Back to search

Ireland· IE-PA-EU/1/15/1059/005

Orkambi 100 mg/125 mg film-coated tablets

A ivacaftor and lumacaftor product containing lumacaftor + ivacaftor, registered in Ireland by Vertex Pharmaceuticals (Ireland) Limited. The same ATC class is registered in 16 of our 19 countries.

ATC R07AX30

Checked against HPRA (Ireland) on

Informational only — not a medical device.

SOURCE REGISTER · IEHPRA (Ireland)normalisedOrkambi 100 mg/125 mg film-coated tab…ATCR07AX30REGISTER NO.IE-PA-EU/1/15/1059/005PACKS LISTED1CHECKEDSeptember 28, 2026

Where it is registered

Ivacaftor and lumacaftor is registered in 16 of 19 countries.

Countries holding a registration under ATC R07AX30 (ivacaftor and lumacaftor), each read from that country’s own register.

  • This record: Ireland, from HPRA (Ireland)
  • 11 of them publish a price we can compare per daily dose

Ivacaftor and lumacaftor · ATC R07AX30

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

HPRA (Ireland)
Active substance
Lumacaftor + Ivacaftor
Manufacturer
Vertex Pharmaceuticals (Ireland) Limited
Country
Ireland (IE)
ATC code
R07AX30
ATC class
Ivacaftor and lumacaftor
Reimbursed
Not published by this register
Source register
HPRA (Ireland)
Last checked
September 28, 2026

Packs & prices · 1

  • ie_pa_number
    EU/1/15/1059/005

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/672c4229-67bd-4fe8-9734-faaf2cada9ea
GET /v1/drugs/672c4229-67bd-4fe8-9734-faaf2cada9ea?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Film-coated tablet",
  "routes": [
    "Oral use"
  ],
  "source": "hpra",
  "atc_all": [
    "R07AX",
    "R07AX30"
  ],
  "strength": null,
  "pa_number": "EU/1/15/1059/005",
  "substances": [
    "Lumacaftor",
    "Ivacaftor"
  ],
  "legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
  "market_info": "Unknown",
  "authorised_at": "08/01/2018",
  "dispensing_status": "Product subject to prescription which may not be renewed (A)",
  "registration_status": "AU",
  "supply_legal_status": "Supply through pharmacies only",
  "interchangeable_code": null
}

See everything about ivacaftor and lumacaftor.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.